2024 年业绩略高于我们预期公司公布2024 年业绩：收入122.61 亿元，同比增长21.3%；归母净利润43.72 亿元，同比增长33.4%，业绩高于我们预期，主因产品对外授权的首付款记账以及阿美乐销售高速放量。发展趋势创新药收入占比持续提升。2024 年公司创新药与合作产品收入94.77 亿元，同比增长38.1%，占比提升至77.3%（+9.4pct YoY），其中合作产品收入为15.73...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.